Elisabeth Eppard

List of Publications by Year
in descending order

25 papers	1,343 citations	471509 17 h-index	580821 25 g-index
26 all docs	26 docs citations	26 times ranked	1329 citing authors

#	Article	IF	Citations
1	Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget, 2016, 7, 12477-12488.	1.8	226
2	Response and Tolerability of a Single Dose of¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Journal of Nuclear Medicine, 2016, 57, 1334-1338.	5.0	178
3	Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1448-1454.	6.4	138
4	The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1473-1479.	6.4	104
5	Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-PSMA-617. Journal of Nuclear Medicine, 2017, 58, 312-319.	5.0	103
6	Clinical Translation and First In-Human Use of [⁴⁴Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics, 2017, 7, 4359-4369.	10.0	94
7	Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget, 2017, 8, 55094-55103.	1.8	66
8	Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 19.	3.9	61
9	Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget, 2017, 8, 55567-55574.	1.8	59
10	Ethanol-Based Post-processing of Generator-Derived ⁶⁸Ga Toward Kit-Type Preparation of ⁶⁸Ga-Radiopharmaceuticals. Journal of Nuclear Medicine, 2014, 55, 1023-1028.	5.0	56
11	Theranostic Advances in Breast Cancer in Nuclear Medicine. International Journal of Molecular Sciences, 2021, 22, 4597.	4.1	38
12	Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases. Annals of Nuclear Medicine, 2019, 33, 404-413.	2.2	29
13	Improved radiolabeling of DOTATOC with trivalent radiometals for clinical application by addition of ethanol. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 6.	3.9	24
14	Cation exchange-based post-processing of 68Ga-eluate: A comparison of three solvent systems for labelling of DOTATOC, NO2APBP and DATAm. Applied Radiation and Isotopes, 2015, 98, 54-59.	1.5	21
15	Improved Efficacy of Synthesizing *M^{III}-Labeled DOTA Complexes in Binary Mixtures of Water and Organic Solvents. A Combined Radio- and Physicochemical Study. Inorganic Chemistry, 2018, 57, 6107-6117.	4.0	21
16	Evaluation of Safety and Dosimetry of ¹⁷⁷Lu-DOTA-ZOL for Therapy of Bone Metastases. Journal of Nuclear Medicine, 2021, 62, 1126-1132.	5.0	21
17	Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results. EJNMMI Research, 2019, 9, 102.	2.5	20
18	An Impressive Approach in Nuclear Medicine. PET Clinics, 2021, 16, 327-340.	3.0	16

#	Article	IF	Citations
19	Optimization of Labeling PSMA^{HBED} with Ethanol-Postprocessed ⁶⁸Ga and Its Quality Control Systems. Journal of Nuclear Medicine, 2017, 58, 432-437.	5.0	14
20	DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasisâ€"Challenges and Critical Points in Implementation into Clinical Routine. Molecules, 2020, 25, 2988.	3.8	12
21	Ethanol effects on 68Ga-radiolabelling efficacy and radiolysis in automated synthesis utilizing NaCl post-processing. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 26.	3.9	11
22	Quantitative online isolation of 68Ge from 68Ge/68Ga generator eluates for purification and immediate quality control of breakthrough. Applied Radiation and Isotopes, 2013, 82, 45-48.	1.5	10
23	Manual vs automated ⁶⁸Gaâ€radiolabellingâ€"A comparison of optimized processes. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 162-173.	1.0	9
24	A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies. Cancers, 2022, 14, 1779.	3.7	7
25	68Ge content quality control of 68Ge/68Ga-generator eluates and 68Ga radiopharmaceuticals â€“ A protocol for determining the 68Ge content using thin-layer chromatography. Applied Radiation and Isotopes, 2014, 91, 92-96.	1.5	4